Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$105.25 USD
-0.21 (-0.20%)
Updated May 31, 2024 04:00 PM ET
After-Market: $105.27 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Jazz Pharmaceuticals PLC [JAZZ]
Reports for Purchase
Showing records 21 - 40 ( 248 total )
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Current Biz Justifies Meaningful Upside Here, With Free Call on Pipeline and Accretive MA, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Takeaways from Company Presentations at Tremor Congress 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Xywav Solid 2023 Start Despite New Competition Bolsters Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
2023 Guidance: When an Expected Divot Year is Actually a Revenue Growth Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Solid Top Line and Big Cost Cuts Leave Plenty of Flexibility for R&D Investment and M&A; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O